Cardiovascular Health

Vutrisiran becomes the first and only therapeutic FDA-approved to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.

Factor XI inhibitors show promise as a safer alternative to direct oral anticoagulants for preventing and treating thrombosis, offering similar efficacy with reduced bleeding risk.

The treatment is indicated for patients aged 6 and older with hypertension, the reduction of stroke in hypertension and left ventricular hypertrophy, and diabetic nephropathy in certain patients with type 2 diabetes.

The new indication would include adults with heart failure with a left ventricular ejection fraction (LVEF) of 40% or higher, such as mildly reduced or preserved LVEF.

This study found no significant difference in the sustained return of spontaneous circulation or survival to hospital discharge based on the timing of the first epinephrine administration in these patients.

Although improvements were observed in blood pressure (BP) medication adherence, there were no improvements in stain or glucose-lowering medication use.

If approved, vutrisiran would be the first FDA-approved therapy to treat both the polyneuropathy and cardiomyopathy aspects of transthyretin amyloidosis (ATTR).

Pharmacists also educate, advocate, and ensure patients with heart failure with reduced ejection fraction (HFrEF) and anemia are receiving the appropriate regimens.

In a clinical trial, tenecteplase was shown to be a comparable alternative to alteplase.

The feature is expected to be available to US users in late March 2025.

Levonorgestrel-releasing intrauterine devices were not found to increase women’s risks of these conditions.

Educating patients about lifestyle modifications is a critical part of preventing cerebrovascular events.

These findings may lead to new therapies to help reduce the risk of heart disease in women who are at risk.

Future research can explore the underlying cause of recurrent pericarditis with systemic Sjögren syndrome and the combination of rilonacept with immunosuppressive therapies.

Pharmacists can help educate patients, identify adverse events, and help patients communicate with other health care professionals or drug companies.

The decision to end HYPERION (NCT04811092) comes after positive results from an interim analysis of the ZENITH trial (NCT04896008).

Vietnam war trauma continues to affect veterans’ health 50 years later.

The prevention of preeclampsia may reduce severe maternal morbidity (SMM) risk in pregnant people.

The initiative will provide information about care models for specialists and clinical teams to improve patient outcomes in heart failure.

Angiotensin receptor neprilysin inhibitors show promise as an alternative to standard management of resistant hypertension.

Hypertrophic cardiomyopathy is caused by abnormal genes in the heart muscle, causing the left ventricle to become thicker and effecting blood flow.

Although the research focused on Black communities in the United States, there is also evidence linking racism and blood pressure for patients who are Asian or Hispanic.

Pharmacists can play an important role in tobacco cessation.

The drug is being investigated as a PET diagnostic of cardiac amyloid light-chain and amyloid transthyretin-related (ATTR) amyloidosis.

Raising awareness of the potentially fatal cardiovascular complications of epinephrine toxicity.

Investigators found that the polypill treatment improved cardiovascular disease and lowered health care costs.

Posttraumatic stress disorder is found to be associated with coronary artery disease, hypertension, and heart failure.

ALG-801 could present new opportunities to improve treatment and management of patients with pulmonary arterial hypertension, a life-threatening condition.

Depression and cardiovascular disease are often linked, with research showing inflammation is common for the 2 disease states.

Certain laboratory tests indicate stronger predictions for hospital stay, suggesting pharmaceutical intervention could help reduce the length of cardiovascular-related hospital stay.